Why Oneida Financial (ONFC) Is With Unusual Volume More Than Transatlantic Petroleum (TAT), Bio-Path (BPTH), Northwest Biotherapeutics (NWBO)

Oneida Financial Corp. (ONFC) and the company’s wholly-owned subsidiary The Oneida Savings Bank reported that Michael Kallet, most lately the President and Chief Executive Officer or CEO of Oneida Financial Corp., will serve as the Chairman of the Board and CEO of both the company and the Bank. The company also remarked that Eric Stickels, recent Executive Vice President and Chief Financial Officer or CFO of the company and President and Chief Operating Officer or COO of the Bank, will serve as the President and COO of both the company and the Bank. In addition, the company stated Deresa Durkee has been promoted to the position of Senior Vice President and Chief Financial Officer of both Oneida Financial Corp. The price of Oneida Financial Corp. (ONFC), Savings & Loans company, stock dropped -0.23% to $12.51. The stock is dealing at -21.12% below its 52-week high and 9.77% above its 52-week low. At the closing bell, shares in Oneida Financial Corp. recorded a trading volume of 33234. Its total outstanding shares are 7.02 million with the market capitalization of $87.83 million. ONFC showed 0.81% weekly performance.

TransAtlantic Petroleum Ltd expects to exit FY 2014 with a production rate of 6,000 – 6,500 BOEPD. Company anticipates oil to comprise at least 70 pct of forecasted production. TransAtlantic Petroleum Ltd. (TAT), Oil & Gas Drilling & Exploration company, flourished 12.95% in last trading session and ended the day on $10.90. The stock is trading -0.91% below its 52-week high and 65.15% above its 52-week low. Company’s forward price to earnings ratio is 8.21x with-2.60% EPS growth and -20.50% Sales growth quarter over quarter. TAT’s year to date performance is 28.24%. Experts rate it a ‘Buy’ stock.

Bio Path Holdings Inc announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market. Effective March 10 , the stock will trade on the NASDAQ Capital Market under the symbol BPTH. Bio-Path Holdings, Inc. (BPTH), Drug Delivery, is currently trading at $3.40, which flourished 5.26%. The stock is trading -35.24% below its 52-week high and 750.00% above its 52-week low. BPTH has $303.38 million market capitalization. The stock recorded a trading volume of 1246862 shares as compared to its average volume of 190.51 million shares. BPTH’s year to date performance is -15.00%. Investment experts consider it a ‘Buy’ stock.

Northwest Biotherapeutics (NWBOW,NWBO,NWBS.L) declared it has initiated the Phase III trial of DCVax-L in Germany. The company noted the first German site is now starting to screen patients for purposes of enrollment. The company has scheduled the full-day site initiations for 3 over and above sites during June and 4 more sites in July. Linda Powers, CEO of NW Bio, said: “We are excited to have the Phase III DCVax-L trial open for enrollment in Germany.” The price of Northwest Biotherapeutics, Inc. (NWBO), Biotechnology company, stock fostered 15.14% to $8.82. The stock is dealing at -17.11% below its 52-week high and 184.52% above its 52-week low. At the closing bell, shares in Northwest Biotherapeutics, Inc. recorded a trading volume of 5385549. Its total outstanding shares are 57.19 million with the market capitalization of $504.42 million. NWBO showed 50.26% weekly performance. Investment experts consider it a ‘Buy’ stock.

About

Jennifer McKinney, CFA, is an equity analyst for The Downtown Leader. If you have a great story idea for Jennifer McKinney, you can write at [Jennifer.McKinney@downtownleader.com ].

POST YOUR COMMENTS